Skip to content
value.today

Anacor Pharmaceuticals Inc

Formerly AnaMax, Inc.

Total raised
$15 M
2 rounds on record
Latest round
$5 M
Apr 2013
First round on record
Nov 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Anacor Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2013$5 MNo. 2$2 to $10 million

Anacor Pharmaceuticals Inc: Raise no. 2, Apr 2013

Investors in this round

1 investor had bought by the notice of Apr 9, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 21 investors are named for Anacor Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Perry · Executive Officer, Director
  • Geoffrey Parker · Executive Officer
  • Jacob Plattner · Executive Officer
  • Kirk Maples · Executive Officer
  • Lee Zane · Executive Officer
  • Anders Hove · Director
  • Lucy Shapiro · Director
  • Mark Leschly · Director
  • Paul Berns · Director
  • Paul Klingenstein · Director
  • William Rieflin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lucy O. Day, Vice President, Finance. Source: SEC Form D, newest notice filed Apr 9, 2013. Read the notice at the SEC.

equitySEC
Nov 2010$10 MNo. 1$10 to $50 million

Anacor Pharmaceuticals Inc: Raise no. 1, Nov 2010

Investors in this round

2 investors had bought by the notice of Dec 3, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 21 investors are named for Anacor Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Perry · Executive Officer, Director
  • Geoffrey Parker · Executive Officer
  • Irwin Heyman · Executive Officer
  • Jacob Plattner · Executive Officer
  • Kirk Maples · Executive Officer
  • Anders Hove · Director
  • Lucy Shapiro · Director
  • Mark Leschly · Director
  • Paul Klingenstein · Director
  • Richard Markham · Director
  • Zhi Hong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark B Weeks, Secretary. Source: SEC Form D, newest notice filed Dec 3, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Anacor Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Apr 2013).

    SEC Form D · Apr 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2013

That is all the official record says: Anacor Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

21 named in official filings. Open an investor to see everything it has backed.

Investors in Anacor Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Aberdare GP II, L.L.C.Othernot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Aberdare II Annex Fund L.P.Fund or asset managernot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Aberdare Ventures II (Bermuda), L.P.Venture capitalnot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Aberdare Ventures II, L.P.Venture capitalnot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Care Capital Investments II LPFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Care Capital Offshore Investments II LPFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Lucy ShapiroPersonnot statednot statedHeld Series A-2 and C preferred stock, director (Form 3, 2010)SEC Form 3
Paul H. KlingensteinPersonnot statednot statedHeld Series A-1, B, C, D and E preferred (Form 3, 2010)SEC Form 3
Rho Capital Partners IncFund or asset managernot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Rho Capital Partners Verwaltungs GmbhFund or asset managernot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Rho Management Trust IFund or asset managernot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Rho Management Ventures IV LLCVenture capitalnot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Rho Ventures IV Gmbh & Co Beteiligungs KGVenture capitalnot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Rho Ventures IV LPVenture capitalnot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Rho Ventures IV QP LPVenture capitalnot statednot statedHeld Series A-1, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
VEF Management IV, LLCFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Associates IV L.P.Fund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Entrepreneurs Fund IV L.P.Fund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Management IV, LLCFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Partners, L.P.Fund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Partners Management, LLCFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Anacor Pharmaceuticals Inc
NameRoleNamed in
David PerryExecutive officerApr 2013
Geoffrey ParkerExecutive officerApr 2013
Jacob PlattnerExecutive officerApr 2013
Kirk MaplesExecutive officerApr 2013
Lee ZaneExecutive officerApr 2013
Irwin HeymanExecutive officerDec 2010
Anders HoveDirectorApr 2013
David PerryDirectorApr 2013
Lucy ShapiroDirectorApr 2013
Mark LeschlyDirectorApr 2013
Paul BernsDirectorApr 2013
Paul KlingensteinDirectorApr 2013
William RieflinDirectorApr 2013
Richard MarkhamDirectorDec 2010
Zhi HongDirectorDec 2010